Thomas P. Richardson PhD, MBA’s Post

ILSE announces winners of inaugural translational research competition!

ILSE's Translational Research Competition will be held next week at Kean University on October 17! Join us as academic and industry scientists in the NJ, NY, and MA region present their translational life science programs. Registration is free but required. https://lnkd.in/eF_bqy9n   The Finalists who will compete for $50,000 in awards include those from the following organizations: Cornell University Culnexin Therapeutics, Inc. Gosia Genomics Inc. Hackensack Meridian Health-Center for Discovery and Innovation Lactiga NP Pharma Princeton Rutgers U-Massachusetts Chan Medical School Weill Cornell Medicine   Winners will work with the ILSE team and sponsors to develop translational research plans aimed at maximizing success for the technology.

Institute for Life Science Entrepreneurship and Kean University hosted a recent press conference with US Senators Bob Menendez and Cory Booker highlighting the Federal Appropriation to expand ILSE's incubator on campus

ILSE receives $2.5M Federal appropriation to expand life science incubator. #lifescience #KeanUniversity #entrepreneurship

Symposium on translational research in infectious diseases! 12/16 Friday hosted by ILSE at Kean University. We are excited to host the first symposium on translational research in infectious diseases and to issue a call for posters for the program.  Registration is free but required: https://lnkd.in/eGKMgn9Q    Join us and connect with researchers and business representatives from the CARB-X, Hackensack Meridian School of Medicine-CDI, ILSE, Johnson & Johnson, Merck, Princeton, Regeneron, Rutgers, and innovative startups as they present their work and perspectives on drug discovery and business partnering. Networking opportunities are open throughout the program and an interactive poster session will follow lunch. Sponsors include NJ Commission on Science, Innovation and Technology, New Jersey Health Foundation, ILSE, Kean University, Princeton University, and Rutgers University.

CARB-X launched a Spotlight today about Pattern Bioscience and its first-in-kind rapid diagnostic that uses artificial intelligence (AI) to identify bacterial pneumonia and provide definitive results in hours. No other diagnostic with this speed and precision is available on the market for bacterial pneumonia, among the world’s most deadly communicable diseases. Pattern received Breakthrough Device Designation from the FDA to receive priority review as the company aims to begin clinical trials in 2023. Expanded write up of this technology are in the following feeds https://lnkd.in/eQiE_VKW https://lnkd.in/e2MCAbXa

We are excited to announce that Kathera Bioscience, a company incubated at ILSE, has received a $150,000 CATALYST award from New Jersey's Commission on Science, Innovation and Technology.